{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:51:43Z","timestamp":1761562303463,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.carrev.2017.09.003","type":"journal-article","created":{"date-parts":[[2017,9,10]],"date-time":"2017-09-10T10:31:08Z","timestamp":1505039468000},"page":"338-342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PB","title":["Bivalirudin versus heparin, without glycoprotein inhibition, in percutaneous coronary intervention: A comparison of ischemic and hemorrhagic outcomes over 10 years"],"prefix":"10.1016","volume":"19","author":[{"given":"Hannah I.","family":"Chaudry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore B.","family":"Curran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce W.","family":"Andrus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila M.","family":"Conley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James T.","family":"DeVries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.carrev.2017.09.003_bb0005","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1161\/01.CIR.103.24.3019","volume":"103","author":"Smith","year":"2001","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.carrev.2017.09.003_bb0010","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jcin.2011.02.011","volume":"4","author":"Mehran","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"issue":"7","key":"10.1016\/j.carrev.2017.09.003_bb0015","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.carrev.2017.09.003_bb0020","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.carrev.2017.09.003_bb0025","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMoa0802944","article-title":"Bivalirudin versus unfractionated heparin during percutaneous coronary intervention","volume":"359","author":"Kastrati","year":"2008","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.carrev.2017.09.003_bb0030","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.carrev.2017.09.003_bb0035","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1093\/eurheartj\/ehq330","article-title":"ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention","volume":"31","author":"Schulz","year":"2010","journal-title":"Eur Heart J"},{"issue":"21","key":"10.1016\/j.carrev.2017.09.003_bb0040","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1056\/NEJMoa1109596","article-title":"Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction","volume":"365","author":"Kastrati","year":"2011","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.carrev.2017.09.003_bb0045","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","article-title":"Bivalirudin started during emergency transport for primary PCI","volume":"369","author":"Steg","year":"2013","journal-title":"N Engl J Med"},{"issue":"9943","key":"10.1016\/j.carrev.2017.09.003_bb0050","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0140-6736(14)61216-2","article-title":"Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials","volume":"384","author":"Cavender","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.carrev.2017.09.003_bb0055","doi-asserted-by":"crossref","first-page":"e000258","DOI":"10.1136\/openhrt-2015-000258","article-title":"Bivalirudin versus unfractionated heparin: a meta-analysis of patients receiving percutaneous coronary intervention for acute coronary syndromes","volume":"2","author":"Farag","year":"2015","journal-title":"Open Heart"},{"issue":"8","key":"10.1016\/j.carrev.2017.09.003_bb0060","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.recesp.2016.01.036","article-title":"Bivalirudin versus unfractionated heparin in acute coronary syndromes: an updated meta-analysis of randomized trials","volume":"69","author":"Verdoia","year":"2016","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.carrev.2017.09.003_bb0065","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijcard.2016.01.206","article-title":"Efficacy and safety of bivalirudin versus heparin in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials","volume":"209","author":"Zhang","year":"2016","journal-title":"Int J Cardiol"},{"issue":"9565","key":"10.1016\/j.carrev.2017.09.003_bb0070","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(07)60450-4","article-title":"Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the acute catheterization and urgent intervention triage strategy (ACUITY) trial","volume":"369","author":"Stone","year":"2007","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.carrev.2017.09.003_bb0075","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1507854","article-title":"Bivalirudin or unfractionated heparin in acute coronary syndromes","volume":"373","author":"Valgimigli","year":"2015","journal-title":"N Engl J Med"},{"issue":"9957","key":"10.1016\/j.carrev.2017.09.003_bb0080","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","article-title":"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial","volume":"384","author":"Shahzad","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2017.09.003_bb0085","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1706443","article-title":"Bivalirudin versus heparin monotherapy in myocardial infarction","author":"Erlinge","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838917303469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838917303469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:13:50Z","timestamp":1761560030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838917303469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1553838917303469"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2017.09.003","relation":{},"ISSN":["1553-8389"],"issn-type":[{"type":"print","value":"1553-8389"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bivalirudin versus heparin, without glycoprotein inhibition, in percutaneous coronary intervention: A comparison of ischemic and hemorrhagic outcomes over 10years","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2017.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}